Cargando…

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

Detalles Bibliográficos
Autores principales:	Lykopoulos, K, Collins, P, Hall, M, Ehness, R, Barth, J, Louahed, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072007/ http://dx.doi.org/10.1186/2051-1426-2-S2-P16

Ejemplares similares

Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses
por: Gérard, Catherine, et al.
Publicado: (2014)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
por: Baurain, Jean-François, et al.
Publicado: (2018)

Transpositional immunity: immunotherapeutical approach against bovine leukemia virus
por: Roa-Castellanos, RA
Publicado: (2009)

Identification of potential immunotherapeutic targets in antigen presentation and costimulation networks
por: Spaapen, Robbert, et al.
Publicado: (2014)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
por: Amano, M, et al.
Publicado: (2014)

IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
por: Bilyard, Hilary, et al.
Publicado: (2014)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023)

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
por: Wang, Liang-Chuan S, et al.
Publicado: (2015)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Mouse models for pretesting of immunotherapeutic strategies for cancer patients
por: Burchell, JM, et al.
Publicado: (2003)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma
por: Liu, Bai, et al.
Publicado: (2014)

Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors
por: Vellani, Shahnaz D., et al.
Publicado: (2023)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Editorial: Complement and Immunotherapeutics
por: Okrój, Marcin, et al.
Publicado: (2021)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
por: Morse, Michael, et al.
Publicado: (2013)

P338: SLC7A11 PROMOTES ARGININE BIOSYNTHESIS IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMMUNOTHERAPEUTIC POTENTIAL
por: LI, Jiazheng, et al.
Publicado: (2023)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

Coronavirus Immunotherapeutic Consortium Database
por: Mahita, Jarjapu, et al.
Publicado: (2023)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
por: Saiag, P., et al.
Publicado: (2016)

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES
por: Martinez-Verbo, Laura, et al.
Publicado: (2023)

Allergic mechanisms and immunotherapeutic strategies /
Publicado: (1997)

Immunotherapeutic Intervention against Sarcomas
por: Pedrazzoli, Paolo, et al.
Publicado: (2011)

Human Vaccines and Immunotherapeutics: News
por: Riedmann, Eva M
Publicado: (2013)

Peptide-Based Immunotherapeutics and Vaccines
por: Reche, Pedro A., et al.
Publicado: (2014)

Immunotherapeutic strategies in autoimmune uveitis
por: Papotto, Pedro Henrique, et al.
Publicado: (2014)

Immunotherapeutic Potential of Extracellular Vesicles
por: Zhang, Bin, et al.
Publicado: (2014)

Human Vaccines and Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2013)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2012)

MicroRNAs as novel immunotherapeutics
por: Heimberger, Amy B, et al.
Publicado: (2013)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2013)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M
Publicado: (2013)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M
Publicado: (2013)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mir2lfv72pb72oo848kthj99u5